Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

22 Feb 2012

Abstract excerpt

PURPOSE: To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL). PATIENTS AND METHODS: Eligible patients had relapsed/refractory HCL after ≥ two prior therapies and required treatment because of abnormal blood counts. Patients received moxetumomab pasudotox 5 to 50 μg/kg every...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22355053
DOI: 10.1200/jco.2011.38.1756

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell LeukemiaPMID 22355053Read ↗

Immunoconjugates in the management of hairy cell leukemia.Semantic proximity Read ↗

Immunoconjugates and new molecular targets in hairy cell leukemia.Semantic proximity Read ↗

Biology and Treatment of Hairy Cell Leukemia.Semantic proximity Read ↗

Update on the biology and treatment options for hairy cell leukemia.Semantic proximity Read ↗

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity Read ↗

Hairy cell leukemia: update and current therapeutic approach.Semantic proximity Read ↗

Historical overview of hairy cell leukemia.Semantic proximity Read ↗

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.Semantic proximity Read ↗

[Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?]Semantic proximity Read ↗

Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.Semantic proximity Read ↗

Chemoimmunotherapy for hairy cell leukemia.Semantic proximity Read ↗

How I manage patients with hairy cell leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.